Cholinergic receptors and neurodegenerative diseases

Pharmacochemistry Library

Volumn 31, Issue C, 2000, Pages 85-89

  Gualtieri, Fulvio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Acetylcholine releasers; Acetylcholinesterase inhibitors; Alzheimer's disease; Cholinergic hypothesis; High affinity choline uptake enhancers; Muscarinic agonists; Muscarinic antagonists; Neurodegenerative diseases; Nicotinic agonists; Parkinson's disease

Indexed keywords

EID: 77957098011     PISSN: 01657208     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0165-7208(00)80004-5     Document Type: Article

References (23)

1. Anonymous. Z-4105. Drugs of the Future 20 (1995) 584
2. Anonymous. Sabcomeline hydrochloride. Drugs of the Future 24 (1999) 113-114
3. Bartus R.T., Dean R.L.I., Beer A.S., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunctions. Science 217 (1982) 408-417
4. Bowen D.M., Smith C.B., White P., and Davidson A.N. Neurotransmitter related enzymes and indexes of hypoxia in senile dementia and other abiothrophies. Brain 99 (1976) 459-496
5. Boyd R.T. The molecular biology of neuronal nicotinic acetylcholine receptors. Crit. Rev. Toxicol. 27 (1997) 299-318
6. Brioni J.D., Morgan S.J., Oneill A.B., Sykora T.M., Postl S.P., Pan J.B., Sullivan J.P., and Arneric S.P. In vivo profile of novel nicotinic ligands with CNS selectivity. Med. Chem. Res. 6 (1996) 487-510
7. Chaki H., Yamabe H., Sugano M., Morita S., Bessho T., Tabata R.K.-I.S., Egawa M., Tobe A., and Morinaka Y. Design and synthesis of 4-acylaminopyridine derivatives: novel high affinity choline uptake enhancers II. Bioorg. Med. Chem. Lett. 5 (1995) 1495-1500
8. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., and Johnson E.C. Pharmacological characterization of recombinant human neuronal acetylcholine receptors h-α-2-β-2, h-α-2-β-4, h-α-3-β-2, h-α-4-β-2, h-α-4-β-4 and h-α-7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280 (1997) 346-356
9. Coyle J.T., Price C.L., and De Long M.R. Alzheimer's disease: a disorder of cortical cholinergic innervations. Science 219 (1983) 1184-1190
10. Davies P., and Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (1976) 1403-1408
11. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raszkiewicz J.L., Kang C.H., Kim D.J.B., Giardina W.J., Wasicak J.T., Garvey D.S., Williams M., and Arneric S.P. (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 270 (1994) 319-328
12. Doods H., Entzeroth M., Ziegler H., Schiavi G., Engel W., Mihm G., Rudolf K., and Eberlein W. Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur. J. Pharmacol. 242 (1993) 23-30
13. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66 (1999) 137-147
14. Ghelardini C., Galeotti N., Gualtieri F., Scapecchi S., and Bartolini A. 3-α-Tropanyl 2-(4-Cl-phenoxy)butyrate (SM21): a review of the pharmacological profile of a novel enhancer of cholinergic transmission. CNS Drug Reviews 3 (1997) 346-362
15. Glennon R.A., and Dukat M. Nicotine receptor ligands. Med. Chem. Res. 6 (1996) 465-486
16. Gualtieri F., Dei S., Manetti D.,M.N.,R., Scapecchi S., and Teodori E. The medicinal chemistry of Alzheimer and Alzheimer-like diseases with emphasis on the cholinergic hypothesis. II Farmaco 50 7-8 (1995) 489-503
17. Holladay M.K., Lebold S.A., and Lin N.-H. Structure-activity relationships of nicotinic acetylcholine receptor agonists as potential treatments for dementia. Drug Dev. Res. 35 (1995) 191-213
18. Holladay M.W., Dart M.J., and Lynch J.K. Neuronal nicotinic acetylcholine receptors as target for drug discovery. J. Med. Chem. 40 (1997) 4169-4194
19. Kelly J.S. Alzheimer's disease: the tacrine legacy. TIPS 20 (1999) 127-129
20. Lachowicz J.E., Lowe D., Duffy R.A., Rupero W., Taylor L.A., Guzik H., Brown J., Berger J.G., Tice M., McQuade R., Kozlowski J., Clader J., Strader C.D., and Murgolo N. SCH 57790: a novel M2 receptor selective antagonist. Life Sciences 64 (1999) 535-539
21. McGeeer E.G. Neurotransmitter system in aging and dementia. Prog. Neuropsychopharmacol. 5 (1981) 435-445
22. Perry E.K., Perry R.H., Blessed G., and Tomlinson B.E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1 (1977) 189
23. Schenk D.B., Rydel R.E., May P., Little S., Panetta I., Lieberburg I., and Sinha S. Therapeutic approaches related to amyloid beta-peptide and Alzheimer's disease. J. Med. Chem. 38 (1995) 4141-4154